Carmichael Hill & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Carmichael Hill & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.37K	Hold	18	–	–	﹤0.01%	608
2024 Q2	$8.44K	Hold	18	–	–	﹤0.01%	582
2024 Q1	$7.53K	Hold	18	–	–	﹤0.01%	597
2023 Q4	$7.33K	Hold	18	–	–	﹤0.01%	612
2023 Q3	$6.26K	Hold	18	–	–	﹤0.01%	620
2023 Q2	$6.33K	Hold	18	–	–	﹤0.01%	618
2023 Q1	$5.67K	Hold	18	–	–	﹤0.01%	624
2022 Q4	$5.2K	Hold	18	–	–	﹤0.01%	622
2022 Q3	$5K	Hold	18	–	–	﹤0.01%	673
2022 Q2	$5K	Hold	18	–	–	﹤0.01%	667
2022 Q1	$5K	Hold	18	–	–	﹤0.01%	692
2021 Q4	$4K	Hold	18	–	–	﹤0.01%	733
2021 Q3	$3K	Hold	18	–	–	﹤0.01%	736
2021 Q2	$4K	Hold	18	–	–	﹤0.01%	698
2021 Q1	$4K	Hold	18	–	–	﹤0.01%	686
2020 Q4	$4K	Buy	+18	New	+$4.13K	﹤0.01%	659

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmichael Hill & Associates's VRTX Position: Q3 2024 in Review

Carmichael Hill & Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2024 at 18 shares worth $8.37K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Carmichael Hill & Associates first reported a position in VRTX in Q4 2020 and has held it in 16 quarters since. The position peaked at $8.44K in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Carmichael Hill & Associates held 18 shares of Vertex Pharmaceuticals worth $8.37K as of Q3 2024.
Carmichael Hill & Associates left its Vertex Pharmaceuticals share count unchanged in Q3 2024.
Vertex Pharmaceuticals made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #608 holding.
Carmichael Hill & Associates first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
Carmichael Hill & Associates's Vertex Pharmaceuticals position peaked at $8.44K in Q2 2024.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.